Published in Bone Marrow Transplant on October 01, 2001
Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant (2009) 5.10
T cell immune reconstitution following lymphodepletion. Semin Immunol (2007) 2.35
Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis (2013) 2.17
Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cells. Clin Cancer Res (2009) 1.38
Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood (2010) 1.23
CCL25 increases thymopoiesis after androgen withdrawal. Blood (2008) 1.11
Single cell analysis of complex thymus stromal cell populations: rapid thymic epithelia preparation characterizes radiation injury. Clin Transl Sci (2009) 1.08
Increased plasma-immune cytokines throughout the high-dose melphalan-induced lymphodepletion in patients with multiple myeloma: a window for adoptive immunotherapy. J Immunol (2009) 0.89
Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions. Clin Dev Immunol (2012) 0.88
Pneumococcal conjugate vaccine followed by pneumococcal polysaccharide vaccine; immunogenicity in patients with ataxia-telangiectasia. Clin Exp Immunol (2005) 0.85
Chronic mucocutaneous candidiasis and primary hypothyroidism in two families. Eur J Pediatr (2004) 0.84
Influenza and Pneumococcal Vaccination in Hematological Malignancies: a Systematic Review of Efficacy, Effectiveness, and Safety. Mediterr J Hematol Infect Dis (2016) 0.83
The impact of an early truncating founder ATM mutation on immunoglobulins, specific antibodies and lymphocyte populations in ataxia-telangiectasia patients and their parents. Clin Exp Immunol (2004) 0.81
Post-transplant adoptive T-cell immunotherapy. Best Pract Res Clin Haematol (2008) 0.81
Longitudinal analysis of tetanus- and influenza-specific IgG antibodies in myeloma patients. Clin Dev Immunol (2012) 0.76
Technical and diagnostic performance of five commercial anti-diphtheria toxoid IgG enzyme-linked immunosorbent assay kits. Clin Vaccine Immunol (2010) 0.75
P3 mAb: An Immunogenic Anti-NeuGcGM3 Antibody with Unusual Immunoregulatory Properties. Front Immunol (2012) 0.75
Lymphoma patients undergoing high-dose therapy and ABMT, and EBMJ guidelines. Bone Marrow Transplant (2002) 0.75
FLT3 Ligand regulates thymic precursor cells and hematopoietic stem cells through interactions with CXCR4 and the marrow niche. Exp Hematol (2017) 0.75
Stromal gene signatures in large-B-cell lymphomas. N Engl J Med (2008) 11.34
Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med (1994) 3.73
Risk factors for Toxoplasma gondii infection in pregnancy. Results of a prospective case-control study in Norway. Am J Epidemiol (1996) 2.04
[Treatment with growth factors and cytokines in hematologic diseases]. Tidsskr Nor Laegeforen (1996) 2.03
Treatment of toxoplasmosis during pregnancy: a multicenter study of impact on fetal transmission and children's sequelae at age 1 year. Am J Obstet Gynecol (1999) 1.92
Epidemiology of blindness in Nepal. Bull World Health Organ (1985) 1.91
The past and present role of the Sabin-Feldman dye test in the serodiagnosis of toxoplasmosis. Bull World Health Organ (1999) 1.56
Transformation of amyloid precursor SAA to protein AA and incorporation in amyloid fibrils in vivo. Scand J Immunol (1985) 1.47
Associations among cataract prevalence, sunlight hours, and altitude in the Himalayas. Am J Epidemiol (1983) 1.47
Cells of Th2 cytokine phenotype prevent LPS-induced lethality during murine graft-versus-host reaction. Regulation of cytokines and CD8+ lymphoid engraftment. J Immunol (1994) 1.46
Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine (2003) 1.46
Clinical stage I and II Hodgkin's disease: long-term results of therapy without laparotomy. Experience at one institution. Ann Oncol (1996) 1.45
Persistent changes in the immune system 4-10 years after ABMT. Bone Marrow Transplant (1999) 1.44
Cost-effectiveness of antenatal screening for neonatal alloimmune thrombocytopenia. BJOG (2007) 1.43
Follow-up of breast cancer patients stage I-II: a baseline strategy. Eur J Cancer (1993) 1.39
[High-dose autologous stem cell support in malignant diseases--an established method, uncertain indication]. Tidsskr Nor Laegeforen (1994) 1.39
Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol (2002) 1.37
Second malignancies after treatment of Hodgkin's disease: the influence of treatment, follow-up time, and age. J Clin Oncol (1993) 1.35
Phylogenetic relationship and geographic distribution of multiple human T-cell lymphotropic virus type II subtypes. J Virol (1995) 1.33
Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis. Eur J Cancer (2000) 1.29
Intranasal immunization with heat-inactivated Streptococcus pneumoniae protects mice against systemic pneumococcal infection. Infect Immun (1999) 1.18
Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation. Ann Oncol (2008) 1.17
Human opsonins induced during meningococcal disease recognize outer membrane proteins PorA and PorB. Infect Immun (1999) 1.17
A prospective study of health-related quality of life, fatigue, anxiety and depression 3-5 years after stem cell transplantation. Bone Marrow Transplant (2004) 1.14
Prenatal diagnosis of congenital toxoplasmosis: a multicenter evaluation of different diagnostic parameters. Am J Obstet Gynecol (1999) 1.09
Functional properties of CD19+ B lymphocytes positively selected from buffy coats by immunomagnetic separation. Eur J Immunol (1990) 1.08
Extramedullary plasmacytomas and solitary plasma cell tumours of bone. Eur J Haematol (1990) 1.07
Valvular dysfunction and left ventricular changes in Hodgkin's lymphoma survivors. A longitudinal study. Br J Cancer (2009) 1.06
Knowledge of and attitudes toward complementary and alternative therapies; a national multicentre study of oncology professionals in Norway. Eur J Cancer (2004) 1.05
IgM and IgG response to pneumococcal polysaccharide vaccine in normal individuals and individuals splenectomized due to trauma. Acta Pathol Microbiol Immunol Scand C (1984) 1.05
Transforming growth factor type beta (TGF beta) inhibits G1 to S transition, but not activation of human B lymphocytes. Exp Cell Res (1987) 1.02
Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time. Ann Oncol (2002) 1.02
Diagnosis of congenital toxoplasmosis in the neonatal period: A multicenter evaluation. J Pediatr (1999) 0.97
High level of fatigue in lymphoma patients treated with high dose therapy. J Pain Symptom Manage (2000) 0.96
Relevance of a combined HIV antigen/antibody assay to detect early HIV infections in a low prevalence population: case reports. Clin Lab (2004) 0.96
A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. International Emesis Study Group. Eur J Cancer (1990) 0.96
3H-thymidine uptake in B cell lymphomas--relationship to treatment response and survival. Scand J Haematol (1985) 0.96
Post-treatment parenthood in Hodgkin's lymphoma survivors. Br J Cancer (2007) 0.94
An outbreak of ornithosis in Norway in 1981. Scand J Infect Dis (1984) 0.93
Spontaneous (H)-thymidine uptake in histological subgroups of human B-cell lymphomas. Scand J Haematol (1981) 0.93
An outbreak of hepatitis A among homosexuals linked to a family outbreak. Epidemiol Infect (2002) 0.93
Treatment of Burkitt's/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens. Ann Oncol (2004) 0.93
Human T-cell lymphotropic virus testing of blood donors in Norway: a cost-effect model. Int J Epidemiol (2000) 0.92
Transferrin receptor and B-lymphoblast antigen--their relationship to DNA synthesis, histology and survival in B-cell lymphomas. Int J Cancer (1984) 0.92
Health-related quality of life and its potential prognostic implications in patients with aggressive lymphoma: a Nordic Lymphoma Group Trial. Med Oncol (2001) 0.92
Is preeclampsia an infectious disease? Acta Obstet Gynecol Scand (2001) 0.91
Cost of autologous peripheral blood stem cell transplantation: the Norwegian experience from a multicenter cost study. Bone Marrow Transplant (2005) 0.91
Cross-reacting rheumatoid factors and lupus erythematosus (LE)-factors. Springer Semin Immunopathol (1981) 0.91
Ki67 and 4F2 antigen expression as well as DNA synthesis predict survival at relapse/tumour progression in low-grade B-cell lymphoma. Int J Cancer (1989) 0.91
The amino acid sequence of an amyloid fibril protein AA isolated from the horse. Scand J Immunol (1987) 0.90
Oncogenic aberrations in the p53 pathway are associated with a high S phase fraction and poor patient survival in B-cell Non-Hodgkin's lymphoma. Int J Cancer (2000) 0.89
Opinions on and use of alternative medicine among physicians, nurses and clerks in northern Norway. In Vivo (2000) 0.89
Hodgkin's disease in a national and hospital population: trends over 20 years. Eur J Cancer (1997) 0.89
Management of alloimmune thrombocytopenia. Vox Sang (2007) 0.89
Do patients who are treated with stem cell transplantation have a health-related quality of life comparable to the general population after 1 year? Bone Marrow Transplant (1999) 0.88
Detection of measles- and mumps-specific IgG antibodies in paired serum and oral fluid samples from Norwegian conscripts. Eur J Clin Microbiol Infect Dis (2008) 0.88
Weekly adriamycin versus VAC in advanced breast cancer. A randomized trial. Eur J Cancer Clin Oncol (1986) 0.87
[Antibodies against Herpes simplex virus type 2 among pregnant women in Norway]. Tidsskr Nor Laegeforen (1999) 0.87
Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy. Ann Oncol (2007) 0.87
High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant (2001) 0.87
Detection of diphtheria antitoxin by four different methods. Clin Microbiol Infect (1999) 0.87
Cellular antitumor immune response in women with risk factors for breast cancer. Cancer Res (1979) 0.87
Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study. Ann Hematol (2004) 0.87
Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up. Ann Oncol (2007) 0.86
Use of complementary and alternative therapies: a national multicentre study of oncology health professionals in Norway. Support Care Cancer (2004) 0.86
CHOP versus MACOP-B in aggressive lymphoma--a Nordic Lymphoma Group randomised trial. Ann Oncol (1999) 0.86
Pharmacokinetics and metabolism of doxorubicin after short-term infusions in lymphoma patients. Cancer Chemother Pharmacol (1999) 0.86
Peripheral facial palsy and herpes zoster infection. J Laryngol Otol (1976) 0.86
Socio-medical situation for long-term survivors of Hodgkin's disease: a survey of 459 patients treated at one institution. Eur J Cancer (1998) 0.85
Protective effect of beta-glucan against systemic Streptococcus pneumoniae infection in mice. FEMS Immunol Med Microbiol (2000) 0.85
Pneumococcal conjugate vaccine followed by pneumococcal polysaccharide vaccine; immunogenicity in patients with ataxia-telangiectasia. Clin Exp Immunol (2005) 0.85
Inhibition of polyphosphoinositide breakdown and c-myc induction accompanying inhibition of human B-cell activation by two monoclonal antibodies against the leucocyte common antigen (CD45). Scand J Immunol (1990) 0.84
Serum amyloid A protein in acute myocardial infarction. Acta Med Scand (1986) 0.84
Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy. Br J Haematol (2004) 0.84
A population-based study of spinal metastatic disease in South-East Norway. Clin Oncol (R Coll Radiol) (2009) 0.83
Meningococcal outer membrane vesicle vaccine given intranasally can induce immunological memory and booster responses without evidence of tolerance. Infect Immun (2001) 0.83
Activation of human B cells: alternate options for initial triggering and effects of nonmitogenic concentrations of anti-IgM antibodies on resting and activated cells. J Immunol (1987) 0.83
Loss of chromosome 11q21-23.1 and 17p and gain of chromosome 6p are independent prognostic indicators in B-cell non-Hodgkin's lymphoma. Br J Cancer (2001) 0.83
BK virus infection in patients with AIDS. Scand J Infect Dis (1988) 0.83
c-MYC, RB-1, TP53, and centromere 8 and 17 copy number in B-cell non-Hodgkin's lymphomas assessed by dual-color fluorescence in situ hybridization. Cytometry (1999) 0.83
ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma--the Nordic Lymphoma Group experience. Eur J Haematol (2004) 0.83
Gonadal function in male patients after treatment for malignant lymphomas, with emphasis on chemotherapy. Br J Cancer (2009) 0.83
Gain of chromosome 6p is an infrequent cause of increased PIM1 expression in B-cell non-Hodgkin's lymphomas. Leukemia (2006) 0.83